| Document |
Document Title |
|
WO/2023/051606A1 |
Provided are the medical use of an SHP2 inhibitor in combination with EGFR-TKI in the treatment and prevention of tumor diseases, and the use of the SHP2 inhibitor in the preparation of a drug for treating EGFR-TKI-resistant tumor diseas...
|
|
WO/2023/046200A1 |
The present disclosure relates to a combined pharmaceutical composition of a CDK4/6 inhibitor and an aromatase inhibitor, and the use thereof in the treatment of breast cancer. Compared with separate administration of any agent in the co...
|
|
WO/2023/049364A1 |
The present disclosure is directed to compounds of formula (I):; wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates ...
|
|
WO/2023/049367A1 |
The present disclosure is directed to compounds of formula (I):, wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts...
|
|
WO/2023/049438A1 |
Provided herein are compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-crystals, and prodrugs thereof, pharmac...
|
|
WO/2023/046150A1 |
Disclosed are a sulfonamide compound, a preparation method therefor and a use thereof, belonging to the technical field of pharmaceutical chemistry. The structure of the sulfonamide compound of the present invention is as shown in formul...
|
|
WO/2023/046885A1 |
There is provided herein compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1, ring A and the ring containing Q1 to Q5 have meanings as provided in the description. There is also provided medical uses of such ...
|
|
WO/2023/049369A2 |
The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable sal...
|
|
WO/2023/046149A1 |
Disclosed in the present invention are a quinoxaline compound, an isomer, a solvate, a deuterated derivative, or a pharmaceutically acceptable salt of the compound. R1, R2, R3, R4, R5, and n are defined in detail in the description. In a...
|
|
WO/2023/048118A1 |
A purpose of the present invention is to provide a compound which is suitable for use as a material for the capping layer of an organic EL element, has a high refractive index in the wavelength range of 450-750 nm, and has a low extincti...
|
|
WO/2023/046698A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2023/045366A1 |
Disclosed is a new type pyrrolidine type compound as represented by formula (A), or an isomer, an N-oxide, or a pharmaceutically acceptable salt and prodrug thereof. Also disclosed are a preparation method therefor, and a composition and...
|
|
WO/2023/046133A1 |
Disclosed are a dihydropyrimidine compound, a preparation method therefor and an application thereof, belonging to the technical field of pharmaceutical chemistry. The present invention relates to a dihydropyrimidine compound, the struct...
|
|
WO/2023/046158A1 |
Provided are an azaquinolinone compound, an isomer, a solvate, a deuterated derivative or a pharmaceutically acceptable salt of the compound. In addition, also provided are a drug using the compound, the isomer, the solvate, the deuterat...
|
|
WO/2023/049691A1 |
Compounds of Formula (I) and pharmaceutically active salts thereof are provided, where the variables in Formula (I) are described herein. Such compounds and salts are CDK7 inhibitors that are useful for treating conditions characterized ...
|
|
WO/2023/046055A1 |
Disclosed in the present invention are a substituted heterocyclic compound containing an α-ketone framework, and the use thereof, which relate to the field of medicinal chemistry. Specifically disclosed are a substituted heterocyclic co...
|
|
WO/2023/046743A1 |
The present invention relates to a compound of formula (I) for use in organic electronic devices, a composition comprising a compound of formula (IV) and at least one compound of formula (VIa) to (VId), an organic semiconductor layer com...
|
|
WO/2022/170974A9 |
Provided are a compound of formula (I) that inhibit the activity of PARP7, a stereoisomer thereof, a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, an intermediate to prepare the compound, a process to prep...
|
|
WO/2023/045960A1 |
A pyridine derivative and use thereof. The compound has an obvious inhibitory effect on the activity of KRAS and PI3K proteins, can be used as a KRAS and/or PI3K protein inhibitor, and can be used for preparing a drug for treatment of di...
|
|
WO/2023/044326A1 |
The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl
)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of usin...
|
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2023/042879A1 |
The present invention provides: a compound having coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing same. Provided is a compound represented by formula...
|
|
WO/2023/042914A1 |
Pyrrolidine compounds having an HDAC inhibition activity which are useful for treatment or prevention of diseases involving HDACs are provided. A compound of Formula [I], or a salt thereof, wherein R1 is an optionally substituted 6- to 1...
|
|
WO/2023/044333A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/043836A1 |
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, dis...
|
|
WO/2023/041909A1 |
The disclosures herein relate to novel compounds of Formula (1a) or (1b) or a salt thereof, wherein R1, R2, R3, R4, R8, R9 and R10 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk ...
|
|
WO/2023/039662A1 |
The present disclosure provides compounds according to Formulas I and II: where R1 to R11 independently denote: H; D; a halogen; an optionally substituted straight chain or branched alkyl group; an optionally substituted alkenyl group; a...
|
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
|
WO/2023/041055A1 |
Disclosed is a class of KIF18A inhibitors. Specifically, the present invention relates to a compound as represented by general formula (1), a preparation method therefor, and the use of the compound as represented by general formula (1) ...
|
|
WO/2023/044171A1 |
The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...
|
|
WO/2023/040863A1 |
Provided is a polymorph and application of a pyrimidine derivative and a pharmaceutically acceptable salt thereof. The polymorph and application of the pyrimidine derivative that is an A2A/A2B dual receptor antagonist having the chemical...
|
|
WO/2023/043816A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/020519A9 |
A Compound of formula (I) or (II), a stereoisomer thereof, an atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer, a pharmaceutically acceptable salt of the atropisomer, a prodr...
|
|
WO/2023/040828A1 |
Provided is an siRNA conjugate targeting FAP-positive cells, comprising: a ligand portion targeting FAP, an siRNA portion that inhibits expression of survival genes in FAP-positive cells, and a linker portion located between the ligand p...
|
|
WO/2023/043038A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/041905A1 |
The present invention relates to PI3Kα activating compounds and pharmaceutical compositions comprising the same. The present invention further relates, inter alia, to the treatment of disorders susceptible to treatment by PI3Kα activat...
|
|
WO/2023/040537A1 |
The present disclosure relates to the field of pharmaceutical chemistry, and specifically relates to an aminopyrimidine derivative having a structure represented by general formula (I) or general formula (II), a stereoisomer, pharmaceuti...
|
|
WO/2023/041422A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2023/041061A1 |
Provided are a fused bicyclic derivative, a pharmaceutically acceptable salt, a crystal form thereof and a preparation method therefor. Specifically, provided are a hydrochloride, a mesylate, an acetate and a tartrate of the compound of ...
|
|
WO/2023/043823A1 |
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological...
|
|
WO/2023/040914A1 |
Disclosed are a method for treating cancer with a CDK4/6 inhibitor and a corresponding pharmaceutical use. The CDK4/6 inhibitor is 5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1, 3'-indole]-5'-yl)-nitrogen-(5-(1-methylpiperidin-4-yl...
|
|
WO/2023/043753A1 |
Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed ...
|
|
WO/2023/044509A1 |
The disclosure provides a process for the preparation of compounds with nitrile warheads, e.g., a compound of Formula I, contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
|
|
WO/2023/042177A1 |
The application is directed to enantiomerically enriched compounds of Formula S-I: (S-I) and, in particular, Formula S-II: (S-II), and their salts and solvates, wherein R1, R2, R3, R4, and m are as set forth in the specification, as well...
|
|
WO/2023/039020A1 |
The present invention relates to improved synthetic routes of synthesizing adagrasib. The invention also provides intermediates used in the provided synthetic routes.
|
|
WO/2023/037843A1 |
Provided is a novel double-squaraine dye and a method for producing the same. This double-squaraine dye is characterized by being represented by Formula (I0) shown below. (In Formula (I0), D1 and D2 each represent a heterocyclic group.)
|
|
WO/2023/039275A1 |
The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
|
|
WO/2023/035223A1 |
Provided in the present invention are a pharmaceutical composition containing a therapeutically effective amount of Furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and the...
|
|
WO/2023/036175A1 |
Disclosed in the present invention are a glutarimide compound, and the use thereof. Specifically disclosed are a compound as represented by formula (VII-0) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/036140A1 |
Provided are a 3CLpro protease inhibitor, a pharmaceutical composition containing the compound of formula (I), and a method for treating coronavirus by using the compound.
|
